Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02967393 · ClinicalTrials.gov registry record · Phase 4
Influenza Vaccine Feasibility Study in Children With Persistent Asthma
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT02967393 is a Phase 4 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT02967393, a Phase 4 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is designed to note whether a larger safety study using quadrivalent live attenuated influenza vaccine (LAIV4) versus quadrivalent inactivated influenza vaccine (IIV4)(FLUARIX®), would be feasible in children with persistent asthma. Half of the patients in this study will receive the FLUARIX® influenza vaccine, while the other half will receive a cell cultured quadrivalent inactivated influenza vaccine (ccIIV4)(Flucelvax®) being used as a surrogate for LAIV4.
Interventions
- DRUG ccIIV4
- DRUG IIV4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-10-10 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02967393
The ClinicalTrials.gov registry entry for NCT02967393 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ccIIV4 is the first listed.
NCT02967393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02967393 about?
NCT02967393 is a clinical study titled "Influenza Vaccine Feasibility Study in Children With Persistent Asthma". This study is designed to note whether a larger safety study using quadrivalent live attenuated influenza vaccine (LAIV4) versus quadrivalent inactivated influenza vaccine (IIV4)(FLUARIX®), would be feasible in children with persistent asthma. Half of the patients in this study will receive the FLUA...
What is the current status of trial NCT02967393?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2016-10-10. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT02967393?
The interventions under investigation include: ccIIV4 (DRUG), IIV4 (DRUG).
Who is sponsoring clinical trial NCT02967393?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.